Lytix Biopharma AS (LYTIX) - Total Assets
Based on the latest financial reports, Lytix Biopharma AS (LYTIX) holds total assets worth Nkr81.52 Million NOK (≈ $8.58 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lytix Biopharma AS - Total Assets Trend (2017–2025)
This chart illustrates how Lytix Biopharma AS's total assets have evolved over time, based on quarterly financial data. Also see Lytix Biopharma AS market cap and net worth for the company's overall valuation and market capitalisation.
Lytix Biopharma AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Lytix Biopharma AS's total assets of Nkr81.52 Million consist of 97.4% current assets and 2.6% non-current assets. Review Lytix Biopharma AS (LYTIX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr10.60 Million | 13.0% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr2.09 Million | 2.6% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Lytix Biopharma AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LYTIX live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lytix Biopharma AS's current assets represent 97.4% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2025, down from 74.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is cash and equivalents at 13.0% of total assets.
Lytix Biopharma AS Competitors by Total Assets
Key competitors of Lytix Biopharma AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Lytix Biopharma AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.28 | 3.91 | 2.56 |
| Quick Ratio | 4.28 | 3.91 | 2.56 |
| Cash Ratio | 0.57 | 3.56 | 0.00 |
| Working Capital | Nkr60.88 Million | Nkr107.14 Million | Nkr19.89 Million |
Lytix Biopharma AS - Advanced Valuation Insights
This section examines the relationship between Lytix Biopharma AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.51 |
| Latest Market Cap to Assets Ratio | 0.84 |
| Asset Growth Rate (YoY) | -44.4% |
| Total Assets | Nkr81.52 Million |
| Market Capitalization | $68.78 Million USD |
Valuation Analysis
Near Book Valuation: The market values Lytix Biopharma AS's assets close to their book value (0.84x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Lytix Biopharma AS's assets decreased by 44.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lytix Biopharma AS (2017–2025)
The table below shows the annual total assets of Lytix Biopharma AS from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr81.52 Million ≈ $8.58 Million |
-44.37% |
| 2024-12-31 | Nkr146.53 Million ≈ $15.42 Million |
+129.41% |
| 2023-12-31 | Nkr63.87 Million ≈ $6.72 Million |
-57.98% |
| 2022-12-31 | Nkr152.02 Million ≈ $16.00 Million |
-25.10% |
| 2021-12-31 | Nkr202.96 Million ≈ $21.36 Million |
+522.26% |
| 2020-12-31 | Nkr32.62 Million ≈ $3.43 Million |
+87.09% |
| 2019-12-31 | Nkr17.43 Million ≈ $1.83 Million |
-70.40% |
| 2018-12-31 | Nkr58.90 Million ≈ $6.20 Million |
+25.07% |
| 2017-12-31 | Nkr47.09 Million ≈ $4.96 Million |
-- |
About Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more